Nuo Therapeutics (AURX) 10-Q/A 10 Aug 22 2022 Q2 Quarterly report (amended) Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Aug. 05, 2022
Document Information [Line Items]
Entity Central Index Key	0001091596
Entity Registrant Name	Nuo Therapeutics, Inc.
Amendment Flag	true
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Document Type	10-Q/A
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	000-28443
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	23-3011702
Entity Address, Address Line One	8285 El Rio, Suite 190
Entity Address, City or Town	Houston
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	77054
City Area Code	346
Local Phone Number	396-4770
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Amendment Description	This Amendment No. 1 to Form 10-Q is being filed solely to provide the conformed signature that was inadvertently omitted from the Exhibit 31 certification.  No other changes have been made to the Form 10-Q as originally filed on August 8, 2022.
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		41,081,962

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
ASSETS
Cash and cash equivalents	$ 3,444,828	$ 1,414,569
Inventory	238,172	0
Prepaid expenses and other current assets	188,270	51,349
Total current assets	3,871,270	1,465,918
Property and equipment, net	50,179	0
Operating lease right of use assets	401,702	0
Total assets	4,323,151	1,465,918
LIABILITIES AND STOCKHOLDERS' EQUITY
Common stock; $0.0001 par value, 100,000,000 shares authorized, 41,081,962 and 37,124,205 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	4,109	3,713
Additional paid-in capital	28,450,401	24,382,195
Accumulated deficit	(24,892,499)	(23,593,069)
Total stockholders' equity	3,562,011	792,839
Total liabilities and stockholders' equity	4,323,151	1,465,918
Current liabilities
Accounts payable	391,740	526,557
Accrued liabilities	16,522	146,522
Current portion of operating lease liabilities	56,571	0
Total current liabilities	464,833	673,079
Non-current portion of operating lease liabilities	296,307	0
Total liabilities	761,140	673,079
Commitments and contingencies (Note 7)

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	41,081,962	37,124,205
Common stock, shares outstanding (in shares)	41,081,962	37,124,205

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue:
Revenue	$ 0	$ 0	$ 0	$ 0
Costs of sales	0	0	0	0
Gross profit (loss)	0	0	0	0
Operating expenses
Selling, general and administrative	923,726	6,546	1,445,544	12,267
Total operating expenses	923,726	6,546	1,445,544	12,267
Loss from operations	(923,726)	(6,546)	(1,445,544)	(12,267)
Other income (expense)
Interest expense, net	(324)	0	(324)	0
Other income	0	0	146,438	0
Total other income	(324)	0	146,114	0
Net loss	$ (924,050)	$ (6,546)	$ (1,299,430)	$ (12,267)
Basic and diluted (in dollars per share)	$ (0.02)	$ 0	$ (0.03)	$ 0
Basic and diluted (in shares)	39,779,055	30,258,744	38,458,964	30,258,744
Product [Member]
Revenue:
Revenue	$ 0	$ 0	$ 0	$ 0

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2020	30,258,744
Balance at Dec. 31, 2020	$ 3,026	$ 22,995,854	$ (23,502,399)	$ (503,519)
Net loss			(5,721)	(5,721)
Balance (in shares) at Mar. 31, 2021	30,258,744
Balance at Mar. 31, 2021	$ 3,026	22,995,854	(23,508,120)	(509,240)
Balance (in shares) at Dec. 31, 2020	30,258,744
Balance at Dec. 31, 2020	$ 3,026	22,995,854	(23,502,399)	(503,519)
Net loss				(12,267)
Balance (in shares) at Jun. 30, 2021	30,258,744
Balance at Jun. 30, 2021	$ 3,026	22,995,854	(23,514,666)	(515,786)
Balance (in shares) at Mar. 31, 2021	30,258,744
Balance at Mar. 31, 2021	$ 3,026	22,995,854	(23,508,120)	(509,240)
Net loss			(6,546)	(6,546)
Balance (in shares) at Jun. 30, 2021	30,258,744
Balance at Jun. 30, 2021	$ 3,026	22,995,854	(23,514,666)	(515,786)
Balance (in shares) at Dec. 31, 2021	37,124,205
Balance at Dec. 31, 2021	$ 3,713	24,382,195	(23,593,069)	792,839
Issuance of options to settle related party compensation liabilities		103,333		103,333
Stock compensation expense		6,430		6,430
Net loss			(375,380)	(375,380)
Balance (in shares) at Mar. 31, 2022	37,124,205
Balance at Mar. 31, 2022	$ 3,713	24,491,958	(23,968,449)	527,222
Balance (in shares) at Dec. 31, 2021	37,124,205
Balance at Dec. 31, 2021	$ 3,713	24,382,195	(23,593,069)	792,839
Net loss				(1,299,430)
Balance (in shares) at Jun. 30, 2022	41,081,962
Balance at Jun. 30, 2022	$ 4,109	28,450,401	(24,892,499)	3,562,011
Balance (in shares) at Mar. 31, 2022	37,124,205
Balance at Mar. 31, 2022	$ 3,713	24,491,958	(23,968,449)	527,222
Stock compensation expense		1,082		1,082
Net loss			(924,050)	(924,050)
Issuance of common shares (in shares)	3,957,757
Issuance of common shares	$ 396	3,957,361		3,957,757
Balance (in shares) at Jun. 30, 2022	41,081,962
Balance at Jun. 30, 2022	$ 4,109	$ 28,450,401	$ (24,892,499)	$ 3,562,011

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				6 Months Ended		36 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (924,050)	$ (375,380)	$ (6,546)	$ (5,721)	$ (1,299,430)	$ (12,267)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation					7,512	0
Gain on settlement of accounts payable					(146,438)	0
Depreciation of property and equipment	1,356		0		1,356	0
Amortization of operating lease right of use assets					24,836
Changes in operating assets and liabilities:
Inventory					(238,172)	0
Prepaid expenses and other current assets					(136,921)	(1,500)
Accounts payable					11,621	3,920
Accrued liabilities					(26,667)	0
Operating lease liabilities					(73,660)	0
Net cash used in operating activities					1,875,963	9,847
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment					(51,535)	0
Net cash used in investing activities					(51,535)	0
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock					3,957,757	0
Net cash provided by financing activities					3,957,757	0	$ 1,900,000
NET DECREASE IN CASH AND CASH EQUIVALENTS					2,030,259	(9,847)
Cash and cash equivalents, beginning of period		$ 1,414,569		$ 161,432	1,414,569	161,432
Cash and cash equivalents, end of period	$ 3,444,828		$ 151,585		3,444,828	151,585	$ 1,414,569
SUPPLEMENTAL INFORMATION
Interest expense					324	0
Income taxes					0	0
NON-CASH INVESTING AND FINANCING TRANSACTIONS
Issuance of options to settle accrued compensation liabilities					103,333	0
ROU assets and lease liabilities established at inception of lease					$ 426,538	$ 0

Note 1 - Description of Busines

Note 1 - Description of Business	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Nature of Operations [Text Block]	Note 1 Description of Business Description of Business Nuo Therapeutics, Inc. (“Nuo Therapeutics,” the “Company,” “we,” “us,” or “our”) is a Delaware corporation organized in 1998 1999, 2000, 2001, 11 2002 September 2007, 510 April 2010, February 2012, 2014, 2016, 11. May 1, 2019, April 2021, October 2021 May 2022. Impact of COVID- 19 On March 11, 2020, 19 The extent to which COVID- 19 may not The Company has not June 30, 2022 19.

Note 2 - Recapitalization

Note 2 - Recapitalization	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Recapitalization [Text Block]	Note 2 Recapitalization In anticipation of returning to operational status, the Company undertook several financing transactions during 2019 2021 2018 In September 2018, two “2018 two The notes had an original maturity date nine June 17, 2019). 2018 six two 25 not Throughout the first three 2019, 2018 September 17, 2019. 2018 July 31, 2019. In December 2019, 2018 2018 February 10, 2020. December 10, 2019 February 5, 2020 2020 2019 In November December 2019, “2019 2018 On September 1, 2020, 2019 2019 October 2020 ( 2020 2020 In October 2020 2019 2019 ● Deerfield exchanged its Series A Preferred Stock for 2.7 million shares of Common Stock – note that the Series A Preferred Stock did not ● The Noteholders converted $305,000 of principal and $30,400 of accrued and unpaid interest of their Senior Secured Notes (the Company was in default at the time of the conversion) ● The Noteholders agreed to purchase 487,500 shares of Common Stock for gross proceeds of $195,000 in cash. ● The Noteholders received warrants to purchase 3,977,961 shares of Common Stock at $0.40 per share. ● The Noteholders agreed to cancel the warrants originally issued with the 2019 The settlement of the Series A Preferred Stock was accounted for at fair value. The Company recognized a deemed dividend (contribution) resulting from the gain on the cancellation of its equity classified preferred stock, calculated as the difference between the fair value of the consideration transferred and the carrying value of the preferred stock. In addition, Lawrence S. Atinsky, the Deerfield Investors’ representative on the Company’s board, resigned and the number of Company directors was reduced to four. Outstanding options to purchase common stock held by Mr. Atinsky as of the Effective Date were forfeited. The settlement of the 2019 2019 2019 As part of the Recapitalization, the Company granted to each of three 3 2021 In December 2021, January 31, 2022 ( December 30, 2021. See Notes 5 6

Note 3 - Liquidity and Summary

Note 3 - Liquidity and Summary of Significant Accounting Principles	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 3 Liquidity and Summary of Significant Accounting Principles Liquidity Since our inception, we have financed our operations by raising debt, issuing equity and equity-linked instruments, and executing licensing arrangements, and to a lesser extent by generating royalties and product revenues. In mid- 2019, April 2021 2021, 2020 2019, December 2021, three June 30, 2022, two April 29 May 18, 2022. We have incurred, and continue to incur, recurring losses and negative cash flows. As of June 30, 2022, The accompanying condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the ordinary course of business. The propriety of using the going-concern basis is dependent upon, among other things, the achievement of future profitable operations, the ability to generate sufficient cash from operations, and potential other funding sources, including cash on hand, to meet our obligations as they become due. Although the achievement of future profitable operations and the ability to generate sufficient cash from operations is uncertain at this time, as a result of the closing of the private placements for proceeds of $3,957,757 April 29, May 18, 2022, June 30, 2022 one Basis of Presentation and Principles of Consolidation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Accordingly, they do not December 31, 2021, not may not 10 December 31, 2021. The consolidated financial statements include the accounts of the Company and its wholly owned, controlled, and inactive subsidiary Aldagen, Inc. (“Aldagen”). All significant inter-company accounts and transactions are eliminated in consolidation Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not Cash and Cash Equivalents We consider all highly liquid instruments purchased with an original maturity of three Accounts Receivables, net We expect to generate accounts receivables from the sale of our products. We will provide for an allowance against receivables for estimated losses that may not June 30, 2022 2021 no Inventory Our inventory is produced by third first first 18 two As of June 30, 2022, We will provide for an allowance against inventory for estimated losses that may Property and Equipment Property and equipment is stated at cost less accumulated depreciation and amortization. Assets are depreciated, using the straight-line method, over their estimated useful life ranging from one six June 30, 2022, six June 30, 2022 second 2022 Leases At the inception of a contract, the Company determines if the arrangement is, or contains, a lease. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Rent expense is recognized on a straight-line basis over the lease term. The Company has made certain accounting policy elections whereby the Company (i) does not 12 Revenue Recognition The Company analyzes contracts to determine the appropriate revenue recognition using the following steps: (i) identification of contracts with customers; (ii) identification of distinct performance obligations in the contract; (iii) determination of contract transaction price; (iv) allocation of contract transaction price to the performance obligations; and (v) determination of revenue recognition based on timing of satisfaction of the performance obligation. The Company recognizes revenues upon the satisfaction of its performance obligations (upon transfer of control of promised goods or services to customers) in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. We provide for the sale of our products, including disposable processing sets and supplies to customers. Revenue from the sale of products is recognized upon shipment of products to the customers. We do not not not As more fully described above, we had no revenues from initial commercialization activities in the three six June 30, 2022 no three six June 30, 2021 Stock-Based Compensation The fair value of employee stock options is measured at the date of grant. Expected volatilities are based on the equally weighted average historical volatility from five six June 30, 2022 2021 2022 2021 Risk free rate 1.65% - 2.94% 0.33% Weighted average expected years until exercise 5 - 6 5 Expected stock volatility 100% 100% Dividend yield - - The Company elected to account for forfeitures of stock-based awards as they occur. Income Taxes The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. Tax rate changes are reflected in income during the period such changes are enacted. We measure our deferred tax assets and liabilities using the enacted tax rates that we believe will apply in the years in which the temporary differences are expected to be recovered or paid. A deferred income tax asset or liability is recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carryforwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not not The Company’s policy for recording interest and penalties associated with audits is to record such items as a component of income before taxes. There were no 2022 2021. Basic and Diluted Earnings (Loss) per Share In periods of net loss, basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. In periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For periods of net income, diluted earnings per share is computed using the more dilutive of the “treasury method” or “two class method.” Dilutive earnings per share under the “treasury method” is calculated by dividing net income available to common stockholders by the weighted- average number of shares outstanding plus the dilutive impact of all potential dilutive common shares, consisting primarily of common shares underlying common stock options and stock purchase warrants using the treasury stock method, and convertible notes using the if-converted method. Because none All of the Company’s outstanding stock options and warrants were considered anti-dilutive for the three six June 30, 2022 2021. Six months ended June 30, 2022 Six months ended June 30, 2021 Shares underlying: Common stock options 3,311,667 1,355,001 Stock purchase warrants 233,333 7,098,794 3,545,000 8,453,795 Recently Adopted Accounting Standards In August 2020, 2020 06 December 15, 2023, We have evaluated all other issued and unadopted Accounting Standards Updates and believe the adoption of these standards will not

Note 4 - Property and Equipment

Note 4 - Property and Equipment	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 4 Property and Equipment Property and equipment, net consisted of the following: June 30, 2022 December 31, 2021 Medical equipment $ 387,665 $ 387,665 Office/warehouse equipment 31,569 - Warehouse/production equipment 19,966 - 439,200 387,665 Less accumulated depreciation and amortization (389,021 ) (387,665 ) Property and equipment, net $ 50,179 $ - Depreciation expense was $1,356 for the three six June 30, 2022 three six June 30, 2021. None three six June 30, 2022 2021.

Note 5 - Stock Purchase Warrant

Note 5 - Stock Purchase Warrants	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Stock Purchase Warrants [Text Block]	Note 5 Stock Purchase Warrants The following schedule reflects outstanding stock purchase warrants activities as of: Description June 30, 2022 June 30, 2021 2018 Convertible Notes warrants 233,333 233,333 2020 Replacement warrants - 3,977,961 2020 Compensatory warrants - 2,887,500 Total 233,333 7,098,794 The 2018 June 30, 2022 In connection with the Recapitalization and the conversion of the 2019 five In connection with the Recapitalization and to compensate certain individuals for services performed in maintaining the Company’s viability, the Company issued stock purchase warrants to acquire 2,887,500 shares of the Company’s common stock. The warrants had an exercise price of $0.40, a term of five In connection with the Modification, the Company induced the exercise of existing stock purchase warrants to acquire 6,865,461 shares of the Company’s common stock by reducing the exercise price from $0.40 to $0.20 and requiring exercise by a certain date. All warrants were exercised by December 31, 2021

Note 6 - Equity and Stock-based

Note 6 - Equity and Stock-based Compensation	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 6 Equity and Stock-Based Compensation Under the Second Amended and Restated Certificate of Incorporation, the Company has the authority to issue a total of 101,000,000 shares of capital stock, consisting of 100,000,000 shares of common stock and 1,000,000 shares of preferred stock, par value $0.0001 per share, which will have such rights, powers and preferences as the Board of Directors shall determine. Equity Issuance The Company sold 3,957,757 shares of common stock to certain accredited investors pursuant to Security Purchase Agreements in two April 29 May 18, 2022 Stock-Based Compensation In July 2016, 2016 “2016 August 4, 2016, first January 1, 2017) six may not November 21, 2016, 2016 March 4, 2022, 2016 April 21, 2022, March 2022 2016 June 6, 2022. A summary of stock option activity under the 2016 six June 30, 2022 Stock Options 2016 Omnibus Plan Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term Outstanding at January 1, 2022 1,355,001 $ 0.52 3.90 Granted 1,956,666 $ 0.72 10.00 Exercised - $ - - Forfeited or expired - $ - - Outstanding at June 30, 2022 3,311,667 $ 0.64 7.15 Exercisable at June 30, 2022 2,103,334 $ 0.57 5.64 There were 1,956,666 stock options granted under the 2016 six June, 2022 third 3 six June 30, 2022. three approximately$15,300 six June 30, 2022 one third one June 6, 2022 2016 six June 30, 2022. June 30, 2022, six June 30, 2022. For the three six June 30, 2022, three six June 30, 2021.

Note 7 - Commitments and Contin

Note 7 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 7 Commitments and Contingencies Lease Agreements In January 2022, December 31, 2024. December 31, 2022 April 2022. In February 2022, March 2027. three March 31, 2022 April 1, 2022; April 1, 2022 10%. Operating lease ROU assets are included in right of use assets in the Company's condensed consolidated balance sheet as of June 30, 2022. Total lease costs were approximately $39,000 and $49,500 for the three six June 30, 2022, Future undiscounted cash flows under these leases are: 2022 $ 35,344 2023 109,381 2024 112,833 2025 80,273 2026 82,705 2027 21,284 Total 441,820 Discount factor (88,942 ) Lease liability 352,878 Current lease liability (56,571 ) Non-current lease liability $ 296,307

Note 8 - Subsequent Events

Note 8 - Subsequent Events	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	Note 8 Subsequent Events The Company has evaluated subsequent events through the date the condensed consolidated financial statements were available to be issued. No

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Liquidity, Policy [Policy Text Block]	Liquidity Since our inception, we have financed our operations by raising debt, issuing equity and equity-linked instruments, and executing licensing arrangements, and to a lesser extent by generating royalties and product revenues. In mid- 2019, April 2021 2021, 2020 2019, December 2021, three June 30, 2022, two April 29 May 18, 2022. We have incurred, and continue to incur, recurring losses and negative cash flows. As of June 30, 2022, The accompanying condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the ordinary course of business. The propriety of using the going-concern basis is dependent upon, among other things, the achievement of future profitable operations, the ability to generate sufficient cash from operations, and potential other funding sources, including cash on hand, to meet our obligations as they become due. Although the achievement of future profitable operations and the ability to generate sufficient cash from operations is uncertain at this time, as a result of the closing of the private placements for proceeds of $3,957,757 April 29, May 18, 2022, June 30, 2022 one
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation and Principles of Consolidation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Accordingly, they do not December 31, 2021, not may not 10 December 31, 2021. The consolidated financial statements include the accounts of the Company and its wholly owned, controlled, and inactive subsidiary Aldagen, Inc. (“Aldagen”). All significant inter-company accounts and transactions are eliminated in consolidation
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents We consider all highly liquid instruments purchased with an original maturity of three
Receivable [Policy Text Block]	Accounts Receivables, net We expect to generate accounts receivables from the sale of our products. We will provide for an allowance against receivables for estimated losses that may not June 30, 2022 2021 no
Inventory, Policy [Policy Text Block]	Inventory Our inventory is produced by third first first 18 two As of June 30, 2022, We will provide for an allowance against inventory for estimated losses that may
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment is stated at cost less accumulated depreciation and amortization. Assets are depreciated, using the straight-line method, over their estimated useful life ranging from one six June 30, 2022, six June 30, 2022 second 2022
Lessee, Leases [Policy Text Block]	Leases At the inception of a contract, the Company determines if the arrangement is, or contains, a lease. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Rent expense is recognized on a straight-line basis over the lease term. The Company has made certain accounting policy elections whereby the Company (i) does not 12
Revenue [Policy Text Block]	Revenue Recognition The Company analyzes contracts to determine the appropriate revenue recognition using the following steps: (i) identification of contracts with customers; (ii) identification of distinct performance obligations in the contract; (iii) determination of contract transaction price; (iv) allocation of contract transaction price to the performance obligations; and (v) determination of revenue recognition based on timing of satisfaction of the performance obligation. The Company recognizes revenues upon the satisfaction of its performance obligations (upon transfer of control of promised goods or services to customers) in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. We provide for the sale of our products, including disposable processing sets and supplies to customers. Revenue from the sale of products is recognized upon shipment of products to the customers. We do not not not As more fully described above, we had no revenues from initial commercialization activities in the three six June 30, 2022 no three six June 30, 2021
Share-Based Payment Arrangement [Policy Text Block]	Stock-Based Compensation The fair value of employee stock options is measured at the date of grant. Expected volatilities are based on the equally weighted average historical volatility from five six June 30, 2022 2021 2022 2021 Risk free rate 1.65% - 2.94% 0.33% Weighted average expected years until exercise 5 - 6 5 Expected stock volatility 100% 100% Dividend yield - - The Company elected to account for forfeitures of stock-based awards as they occur.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. Tax rate changes are reflected in income during the period such changes are enacted. We measure our deferred tax assets and liabilities using the enacted tax rates that we believe will apply in the years in which the temporary differences are expected to be recovered or paid. A deferred income tax asset or liability is recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carryforwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not not The Company’s policy for recording interest and penalties associated with audits is to record such items as a component of income before taxes. There were no 2022 2021.
Earnings Per Share, Policy [Policy Text Block]	Basic and Diluted Earnings (Loss) per Share In periods of net loss, basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. In periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For periods of net income, diluted earnings per share is computed using the more dilutive of the “treasury method” or “two class method.” Dilutive earnings per share under the “treasury method” is calculated by dividing net income available to common stockholders by the weighted- average number of shares outstanding plus the dilutive impact of all potential dilutive common shares, consisting primarily of common shares underlying common stock options and stock purchase warrants using the treasury stock method, and convertible notes using the if-converted method. Because none All of the Company’s outstanding stock options and warrants were considered anti-dilutive for the three six June 30, 2022 2021. Six months ended June 30, 2022 Six months ended June 30, 2021 Shares underlying: Common stock options 3,311,667 1,355,001 Stock purchase warrants 233,333 7,098,794 3,545,000 8,453,795
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Standards In August 2020, 2020 06 December 15, 2023, We have evaluated all other issued and unadopted Accounting Standards Updates and believe the adoption of these standards will not

Note 3 - Liquidity and Summar_2

Note 3 - Liquidity and Summary of Significant Accounting Principles (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2022 2021 Risk free rate 1.65% - 2.94% 0.33% Weighted average expected years until exercise 5 - 6 5 Expected stock volatility 100% 100% Dividend yield - -
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Six months ended June 30, 2022 Six months ended June 30, 2021 Shares underlying: Common stock options 3,311,667 1,355,001 Stock purchase warrants 233,333 7,098,794 3,545,000 8,453,795

Note 4 - Property and Equipme_2

Note 4 - Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Property, Plant and Equipment [Table Text Block]	June 30, 2022 December 31, 2021 Medical equipment $ 387,665 $ 387,665 Office/warehouse equipment 31,569 - Warehouse/production equipment 19,966 - 439,200 387,665 Less accumulated depreciation and amortization (389,021 ) (387,665 ) Property and equipment, net $ 50,179 $ -

Note 5 - Stock Purchase Warra_2

Note 5 - Stock Purchase Warrants (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Description June 30, 2022 June 30, 2021 2018 Convertible Notes warrants 233,333 233,333 2020 Replacement warrants - 3,977,961 2020 Compensatory warrants - 2,887,500 Total 233,333 7,098,794

Note 6 - Equity and Stock-bas_2

Note 6 - Equity and Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Stock Options 2016 Omnibus Plan Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term Outstanding at January 1, 2022 1,355,001 $ 0.52 3.90 Granted 1,956,666 $ 0.72 10.00 Exercised - $ - - Forfeited or expired - $ - - Outstanding at June 30, 2022 3,311,667 $ 0.64 7.15 Exercisable at June 30, 2022 2,103,334 $ 0.57 5.64

Note 7 - Commitments and Cont_2

Note 7 - Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2022 $ 35,344 2023 109,381 2024 112,833 2025 80,273 2026 82,705 2027 21,284 Total 441,820 Discount factor (88,942 ) Lease liability 352,878 Current lease liability (56,571 ) Non-current lease liability $ 296,307

Note 2 - Recapitalization (Deta

Note 2 - Recapitalization (Details Textual) - USD ($)				1 Months Ended		2 Months Ended	3 Months Ended		6 Months Ended		9 Months Ended	12 Months Ended
	Feb. 05, 2020	Dec. 10, 2019	Sep. 17, 2018	Dec. 31, 2021	Oct. 31, 2020	Dec. 31, 2019	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2019	Dec. 31, 2020	Nov. 30, 2021	Nov. 30, 2020
Stock Issued During Period, Shares, New Issues (in shares)					487,500
Proceeds from Issuance of Common Stock					$ 195,000
Shares Issued, Price Per Share (in dollars per share)					$ 0.40
Share-based Payment Arrangement, Expense							$ 7,512	$ 0	$ 6,430	$ 0
Class of Warrant or Right, Outstanding (in shares)							233,333	7,098,794	233,333	7,098,794
Three Individuals [Member]
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture (in shares)					962,500
Share-based Payment Arrangement, Expense					$ 333,628
Series A Preferred Stock Converted into Common Stock [Member]
Conversion of Stock, Shares Issued (in shares)					2,700,000
Conversion of the 2018 Convertible Notes into Common Stock [Member]
Repayments of Convertible Debt	$ 350,000
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)	350,000
Conversion of the 2019 Senior Secured Notes into Common Stock [Member]
Debt Conversion, Original Debt, Amount					$ 305,000
Debt Conversion, Original Debt, Accrued Interest, Amount					$ 30,400
Debt Conversion, Converted Instrument, Shares Issued (in shares)					838,487
Debt Instrument, Convertible, Conversion Price (in dollars per share)					$ 0.40
Warrants Issued with the 2018 Convertible Notes [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			466,666
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)							$ 0.15		$ 0.15
Class of Warrant or Right, Outstanding (in shares)							233,333	233,333	233,333	233,333
Warrants Issued with the 2018 Convertible Notes [Member] | Auctus Fund, LLC [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			233,333
Warrants Issued with the 2018 Convertible Notes [Member] | EMA Financial, LLC [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			233,333
Warrants Issued with 2019 Senior Secured Notes [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						457,500
Warrants Issued to Investors [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					3,977,961
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 0.40
Warrants Issued to Three Individuals [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					2,887,500
Modified Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)														6,865,461
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 0.20								$ 0.20	$ 0.40	$ 0.40
Share-based Payment Arrangement, Expense				$ 13,936
Class of Warrant or Right, Outstanding (in shares)				6,865,461
Warrant Modification, Amount				$ 795,592
The 2018 Convertible Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage			12%
Debt Instrument, Face Amount											$ 205,000
Proceeds from Convertible Debt			$ 315,800
Payments of Debt Issuance Costs			$ 34,200
Debt Instrument, Term (Month)			9 months
Debt Instrument, Convertible, Period After Date of Issuance (Month)			6 months
Debt Instrument, Convertible, Conversion Price, Percentage Discount of Common Stock Trading Price			40%
Debt Instrument, Amendment Fee											$ 69,000
Debt Instrument, Amendment Fee, Percent of Face Value											20%
Debt Instrument, Increase (Decrease) in Principal of Each Note											$ 30,000
Repayments of Convertible Debt		$ 220,000
Gain (Loss) on Extinguishment of Debt, Total												$ 246,000
The 2018 Convertible Notes [Member] | Auctus Fund, LLC [Member]
Debt Instrument, Face Amount			$ 175,000
The 2018 Convertible Notes [Member] | EMA Financial, LLC [Member]
Debt Instrument, Face Amount			$ 175,000
The 2019 Senior Secured Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage						12%
Debt Instrument, Face Amount						$ 305,000
Gain (Loss) on Extinguishment of Debt, Total					$ 89,776
Proceeds from Issuance of Senior Long-term Debt						$ 220,000

Note 3 - Liquidity and Summar_3

Note 3 - Liquidity and Summary of Significant Accounting Principles (Details Textual) - USD ($)	3 Months Ended		6 Months Ended		36 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Net Cash Provided by (Used in) Financing Activities, Total			$ 3,957,757	$ 0	$ 1,900,000
Proceeds from Issuance of Private Placement			3,957,757	0
Retained Earnings (Accumulated Deficit), Total	$ (24,892,499)		(24,892,499)		(23,593,069)
Cash and Cash Equivalents, at Carrying Value, Total	3,444,828		3,444,828		$ 1,414,569
Accounts Receivable, after Allowance for Credit Loss, Total	0	$ 0	0	0
Inventory, Finished Goods, Gross	94,000		94,000
Inventory, Raw Materials, Gross	144,000		144,000
Revenue from Contract with Customer, Including Assessed Tax	0	$ 0	$ 0	$ 0
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)			1 year
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)			6 years
Private Placement [Member]
Proceeds from Issuance of Private Placement	$ 3,957,757

Note 3 - Liquidity and Summar_4

Note 3 - Liquidity and Summary of Significant Accounting Principles - Summary Stock Option Valuation Assumptions (Details)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Risk free rate		0.33%
Weighted average expected years until exercise (Year)		5 years
Expected stock volatility	100%	100%
Dividend yield		0%
Minimum [Member]
Risk free rate	1.65%
Weighted average expected years until exercise (Year)	5 years
Dividend yield
Maximum [Member]
Risk free rate	2.94%
Weighted average expected years until exercise (Year)	6 years
Dividend yield

Note 3 - Liquidity and Summar_5

Note 3 - Liquidity and Summary of Significant Accounting Principles - Anti-dilutive Securities Excluded From the Computation of Diluted Earnings (Loss) Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Anti-dilutive securities (in shares)	3,545,000	8,453,795
Share-Based Payment Arrangement, Option [Member]
Anti-dilutive securities (in shares)	3,311,667	1,355,001
Warrant [Member]
Anti-dilutive securities (in shares)	233,333	7,098,794

Note 4 - Property and Equipme_3

Note 4 - Property and Equipment (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Depreciation, Total	$ 1,356	$ 0	$ 1,356	$ 0
Asset Impairment Charges, Total	$ 0	$ 0	$ 0	$ 0

Note 4 - Property and Equipme_4

Note 4 - Property and Equipment - Property and Equipment, Net (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Property, plant, and equipment, gross	$ 439,200	$ 387,665
Less accumulated depreciation and amortization	(389,021)	(387,665)
Property and equipment, net	50,179	0
Medical Equipment [Member]
Property, plant, and equipment, gross	387,665	387,665
Office Warehouse Equipment [Member]
Property, plant, and equipment, gross	31,569	0
Warehouse and Production Equipment [Member]
Property, plant, and equipment, gross	$ 19,966	$ 0

Note 5 - Stock Purchase Warra_3

Note 5 - Stock Purchase Warrants (Details Textual) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021	Nov. 30, 2021	Dec. 31, 2020	Nov. 30, 2020	Oct. 31, 2020	Dec. 31, 2019	Sep. 17, 2018
Warrants Issued with the 2018 Convertible Notes [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.15
Class of Warrant or Right, Outstanding, Weighted Average Remaining Contractual Term (Year)	1 year 3 months
Class of Warrant or Right, Outstanding, Aggregate Intrinsic Value	$ 140,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								466,666
Warrants Issued with 2019 Senior Secured Notes Upon Conversion [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)							$ 0.40
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							3,977,971
Warrants and Rights Outstanding, Term (Year)							5 years
Warrants Issued to Employees [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)						$ 0.40
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						2,887,500
Warrants and Rights Outstanding, Term (Year)						5 years
Modified Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.20	$ 0.40	$ 0.20	$ 0.40
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					6,865,461
Proceeds from Warrant Exercises		$ 1,373,092

Note 5 - Stock Purchase Warra_4

Note 5 - Stock Purchase Warrants - Outstanding Stock Purchase Warrants (Details) - shares	Jun. 30, 2022	Jun. 30, 2021
Outstanding warrants (in shares)	233,333	7,098,794
Warrants Issued with the 2018 Convertible Notes [Member]
Outstanding warrants (in shares)	233,333	233,333
The 2020 Replacement Warrants [Member]
Outstanding warrants (in shares)	0	3,977,961
The 2020 Compensatory Warrants [Member]
Outstanding warrants (in shares)	0	2,887,500

Note 6 - Equity and Stock-bas_3

Note 6 - Equity and Stock-based Compensation (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Oct. 31, 2020	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Mar. 04, 2022	Dec. 31, 2021	Aug. 04, 2016
Authorized Shares, Common and Preferred (in shares)		101,000,000		101,000,000
Common Stock, Shares Authorized (in shares)		100,000,000		100,000,000			100,000,000
Preferred Stock, Shares Authorized (in shares)		1,000,000		1,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.0001		$ 0.0001
Stock Issued During Period, Shares, New Issues (in shares)	487,500
Proceeds from Issuance of Private Placement				$ 3,957,757	$ 0
Issuance of Options to Settle Accrued Compensation Liabilities				103,333	0
Share-based Payment Arrangement, Expense		$ 7,512	$ 0	$ 6,430	$ 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Ending Balance (in shares)		1,208,334		1,208,334
The 2016 Omnibus Plan [Member]
Evergreen Provision, Increase in Number of Shares Authorized Calculation, Percentage Amount of Prior Year's Reserved Shares								6%
Evergreen Provision, Maximum Limit of Increase to Authorized Shares (in shares)								1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)						4,250,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)				1,956,666
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)				0
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		$ 14,200		$ 14,200
The 2016 Omnibus Plan [Member] | Immediately Vested Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in shares)				450,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value				$ 6,430
The 2016 Omnibus Plan [Member] | Incentive Stock Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)				3 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in shares)				1,300,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value				$ 15,300
Share-based Payment Arrangement, Expense				1,082
The 2016 Omnibus Plan [Member] | Additional Paid-in Capital [Member]
Issuance of Options to Settle Accrued Compensation Liabilities				$ 103,333
The 2016 Omnibus Plan [Member] | Senior Management and Board of Directors [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)				206,666
Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Fair Value				$ 3,000
The 2016 Omnibus Plan [Member] | Management, Board of Directors, Service Provider [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)				450,000
The 2016 Omnibus Plan [Member] | Employees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)				1,300,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)				3 years
Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)		3,957,757
Proceeds from Issuance of Private Placement		$ 3,957,757

Note 6 - Equity and Stock-bas_4

Note 6 - Equity and Stock-based Compensation - Stock Option Activity (Details) - The 2016 Omnibus Plan [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Shares outstanding (in shares)	1,355,001
Shares outstanding, weighted-average exercise price (in dollars per share)	$ 0.52
Shares outstanding, weighted-average remaining contractual term (Year)	7 years 1 month 24 days	3 years 10 months 24 days
Shares granted (in shares)	1,956,666
Shares granted, weighted-average exercise price (in dollars per share)	$ 0.72
Shares granted, weighted-average remaining contractual term (Year)	10 years
Shares exercised (in shares)	0
Shares exercised, weighted-average exercise price (in dollars per share)	$ 0
Shares forfeited or expired (in shares)	0
Shares forfeited or expired, weighted-average exercise price (in dollars per share)	$ 0
Shares outstanding (in shares)	3,311,667	1,355,001
Shares outstanding, weighted-average exercise price (in dollars per share)	$ 0.64	$ 0.52
Shares exercisable (in shares)	2,103,334
Shares exercisable, weighted-average exercise price (in dollars per share)	$ 0.57
Shares exercisable, weighted-average remaining contractual term (Year)	5 years 7 months 20 days

Note 7 - Commitments and Cont_3

Note 7 - Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022	Apr. 01, 2022	Jan. 31, 2022	Dec. 31, 2021
Operating Lease, Right-of-Use Asset	$ 401,702	$ 401,702	$ 337,226	$ 89,312	$ 0
Operating Lease, Weighted Average Discount Rate, Percent	10%	10%	10%
Operating Lease, Expense	$ 39,000	$ 49,500
Operating Lease, Liability, Total	$ 352,878	$ 352,878	$ 337,226	$ 89,312

Note 7 - Commitments and Cont_4

Note 7 - Commitments and Contingencies - Future Undiscounted Cash Flows (Details) - USD ($)	Jun. 30, 2022	Apr. 01, 2022	Jan. 31, 2022	Dec. 31, 2021
2022	$ 35,344
2023	109,381
2024	112,833
2025	80,273
2026	82,705
2027	21,284
Total	441,820
Discount factor	(88,942)
Lease liability	352,878	$ 337,226	$ 89,312
Current lease liability	(56,571)			$ 0
Non-current lease liability	$ 296,307			$ 0